|Day Low/High||0.47 / 0.50|
|52 Wk Low/High||0.39 / 2.64|
The company has generated revenues from the lots of newly manufactured Ampligen
First patient treated in the Netherlands
TheStreet's biotech columnist offers his own report card on biotech stocks.
Conference Call Scheduled for Tuesday, November 15, 2016 at 11:00 AM EST
Recent Articles on Hemispherx Biopharma by BioWorld and Pink Sheet Posted to Corporate Website
CEO Says Series of Coordinated Settlements Should Allow the New Management Team to Focus Exclusively on the Company's Long-Term Commercial, Research and Financial Objectives